Register for Upcoming Webinar on DEC. 8 @ 11AM

2024 China NMPA Bluebook is here:

Loading Events


December 10, 2020 @ 1:30 pm

product specific questions about china medical devices

Want to reduce your device’s clinical trial costs and accelerate its time to market in China? It’s possible when you use the latest China National Medical Products Administration (NMPA) regulatory developments to your advantage. Now more than ever, NMPA’s regulatory approval process is going through transformational reform. Devicemakers — especially non-China manufacturers — have more options to supplement the traditional comprehensive clinical trial. Case in point: for the first time, a class III implant device was approved in China without the traditional clinical trial. Its manufacturer did so in just a few months using a real-world study of a small sample size. How? An evolution in real-world data/evidence (RWD/E) over the past year. This implant approval demonstrated that initial clinical use in real-world settings can take place in months, not years for NMPA-unapproved devices. Savvy devicemakers are using the latest regulatory developments to lower clinical trial costs and accelerate time to market. They’re drawing on key factors for China’s clinical strategy and pathways to support their submissions, updates on the RWD pilot program, while considering crucial elements in using overseas clinical data. And you can, too. In this webinar, Grace Fu Palma, CEO of China Med Device, LLC and Jason Zhang, MD, its Clinical Director, will share what you must know and use to do just that. Webinar Takeaways:

    • Different clinical pathways and how to decide which pathway to choose to support the NMPA medical device/in vitro diagnostic (IVD) regulatory submission or postmarket surveillance
    • Key areas you need to pay attention to so as to have the right strategy and tactics to shorten clinical trials and approval times
    • Find out whether your devices qualify for the real-world data/study Hainan program, and how to get into the program
    • Key considerations on the feasibility and justification of overseas clinical data acceptance
    • Strategies to improve the overall contract research organization (CRO) process and get your new products to the Chinese population faster — clinical trial study design and clinical trial protocol, calculation of sample size, on-site management and data integrity

Once you understand these regulatory developments, you’ll reduce your clinical trial costs and get your devices to the Chinese market faster. Join us by registering today.


December 10, 2020
1:30 pm
Event Category: